Police: E-commerce scams cost Malaysians RM63mil in six months
Bukit Aman Commercial Crime Investigation Department (CCID) director Datuk Rusdi Mohd Isa said a total of 5,252 cases were reported between January and June this year, involving multiple digital platforms including Facebook, WhatsApp, Instagram, Telegram, TikTok and Mudah.my.
He said the most common modus operandi involved fake sellers offering non-existent items, which were never delivered despite payment made by victims.
"Other tactics include fraudulent websites designed to appear legitimate, which are used to steal personal and financial information, as well as phishing attacks via email or messaging apps that impersonate e-commerce companies," he told reporters today.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Sun
an hour ago
- The Sun
Fake AI photos of Trump with Epstein spread online
WASHINGTON: Fake AI-generated photos and videos claiming to show former US President Donald Trump with convicted sex offender Jeffrey Epstein have gone viral, raising concerns over misinformation. Researchers found at least seven manipulated images and one video, collectively amassing over 7.2 million views. One widely shared deepfake video depicts Trump and Epstein watching young girls dance, set to Sade's song 'Is it a Crime?' Another fabricated image shows Trump dancing with a teenager on Epstein's private island, captioned with a provocative question about his character. Disinformation watchdog NewsGuard confirmed the content as AI-generated using detection tools like Hive and IdentifAI. While Trump's past association with Epstein is well-documented, no verified photos exist of him with underage girls or on Epstein's island. The surge in AI-generated 'slop'—low-quality synthetic media—highlights growing challenges in distinguishing real from fake content online. Platforms like YouTube and TikTok now host paid courses teaching users how to monetize such viral deepfakes, even as moderation efforts decline. The spread of fake images intensified after the FBI and Justice Department dismissed claims of an Epstein 'client list' on July 7. Trump's MAGA supporters demanded the release of alleged 'Epstein files,' fueling conspiracy theories. Despite a Wall Street Journal report naming Trump among hundreds in Epstein's records, no evidence links him to criminal activity. Trump recently sued the newspaper for defamation over a story about a suggestive letter he allegedly wrote to Epstein. - AFP
The Star
6 hours ago
- The Star
Ukraine anti-corruption chief says his agency faces 'dirty information campaign'
Semen Kryvonos, Director of the National Anti-Corruption Bureau of Ukraine, speaks during an interview with Reuters, amid Russia's attack on Ukraine, in Kyiv, Ukraine July 25, 2025. REUTERS/Yurii Kovalenko KYIV (Reuters) -Ukraine's top anti-corruption investigator said on Friday that he did not expect attempts to derail his agency's work to end, despite an abrupt U-turn by President Volodymyr Zelenskiy on curbing their independence that fuelled rare wartime protests. Semen Kryvonos, director of the National Anti-Corruption Bureau of Ukraine (NABU), said he was taken aback by attempts this week to curtail his agency's fight against graft but did not name those who may have been behind the legislation. "Everyone united around the idea of ruining our independence," Kryvonos told Reuters in an interview in Kyiv, referring to parliament passing the controversial measures. "This was a shock for me - how much demand had built up to destroy us." He spoke a day after Zelenskiy sought to defuse tensions by submitting legislation restoring the independence of NABU and its sister agency, the Specialised Anti-Corruption Prosecutor's Office (SAPO). Thousands of protesters took part in protests in Kyiv and other Ukrainian cities this week after lawmakers fast-tracked a bill granting a Zelenskiy-appointed general prosecutor power over the two bodies. The move had also threatened Kyiv's ties with the European Union and Western donors which have been a critical source of financial and military support during Russia's war in Ukraine. Kryvonos applauded Zelenskiy's reversal, but said NABU and SAPO remain a high-priority target for vested interests aiming to stymie their closely watched efforts to clean up. Parliament will consider Zelenskiy's new bill in a special session next week. But Kryvonos worries corrupt actors will step up a "dirty information campaign" already being waged against NABU on widely read anonymous Telegram channels, casting the agency as slow or ineffective. He did not identify the exact sources of resistance to his agency's work, saying only that they are "various representatives of the government, various financial groups". "Everyone who is offended by NABU and SAPO will be pushing out this message," Kryvonos said. 'SYSTEMIC WORK' AND THREATS Since Russia's February 2022 invasion, Ukraine has stepped up a campaign to eradicate the pervasive graft that has plagued its political culture for decades. Stamping out corruption is both critical to Kyiv's bid to join the EU and its effort to erase a legacy of autocracy and Russian rule. NABU and SAPO, launched with Western support after a 2014 revolution toppled a pro-Russian president, have levelled charges against lawmakers and senior government officials. In recent months, Kryvonos's agency has uncovered huge real estate schemes in the capital Kyiv and accused a then deputy prime minister of taking a $345,000 kickback. Kryvonos suggested such efforts had led to a sweeping crackdown this week that paved the way for the rollback of NABU's and SAPO's powers. Two NABU officials were arrested for suspected ties to Russia and nearly 20 other agency employees searched over lesser alleged infractions in a campaign critics said went too far. "All of this was a result of systemic work by NABU and SAPO, especially over the past half-year," he said, adding that he had also received "a huge amount" of threats. Despite winning a hard-fought victory this week, he said resistance was still widespread enough across the political landscape to pose a serious challenge. He cited the controversial law that had been supported by most of Zelenskiy's political party as well as opposition lawmakers and those associated with former pro-Russian factions. Political elites, Kryvonos said, "need to stop considering us as accept us as an important part of state institutions." (Editing by Timothy Heritage)
Malaysian Reserve
9 hours ago
- Malaysian Reserve
Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk
INDIANAPOLIS, July 25, 2025 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of Verve Therapeutics, Inc. (Nasdaq: VERV). Verve is a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease. 'This acquisition unlocks the opportunity to potentially transform the treatment paradigm for millions of patients worldwide by delivering lifelong cardiovascular risk reduction with a one-and-done treatment,' said Ruth Gimeno, Lilly group vice president, Diabetes and Metabolic Research and Development. 'We are excited to welcome Verve colleagues to Lilly and work together to develop innovative genetic medicines for cardiometabolic disease.' About LillyLilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit and or follow us on Facebook, Instagram, and LinkedIn. F-LLY Cautionary Statement Regarding Forward-Looking StatementsThis press release contains forward-looking statements regarding Lilly's acquisition of Verve, regarding prospective benefits of the acquisition and Verve's gene editing programs for cardiovascular disease, regarding Verve's product candidates and ongoing clinical and preclinical development, and regarding Lilly's development of programs for cardiovascular disease and advancement of cardiometabolic health medicines. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Forward-looking statements reflect current beliefs and expectations; however, these statements involve inherent risks and uncertainties, including with respect to drug research, development and commercialization, Lilly's evaluation of the accounting treatment of the acquisition and its potential impact on its financial results and financial guidance, regulatory changes and developments, the impact of global macroeconomic conditions, including trade and other global disputes and interruptions, including related to tariffs, trade protection measures, and similar restrictions, risks that the acquisition disrupts current plans and operations or adversely affect employee retention, and any legal proceedings that have been or may be instituted related to the acquisition. Actual results could differ materially due to various factors, risks and uncertainties. Among other things, there can be no guarantee that Lilly will realize the expected benefits of the acquisition, that product candidates will be approved on anticipated timelines or at all, that any products, if approved, will be commercially successful, that all or any of the contingent consideration will become payable on the terms described herein or at all, that Lilly's financial results will be consistent with its expected 2025 guidance or that Lilly can reliably predict the impact of the acquisition on its financial results or financial guidance. For further discussion of these and other risks and uncertainties, see Lilly's most recent Form 10-K and Form 10-Q filings with the U.S. Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this press release. Refer to: Ashley Hennessey; gentry_ashley_jo@ 317-416-4363 (Media) Michael Czapar; czapar_michael_c@ 317-617-0983 (Investors)
